IDL Biotech currently has a number of ongoing clinical studies both internationally and in Sweden, with the aim of demonstrating the clinical benefit of UBC® Rapid in bladder cancer and having the test included as a complement in the follow-up of patients with bladder...
News
Bladder cancer
IDL Biotech is planning for clinical studies in the United States of America for its rapid diagnostic test for bladder cancer, UBC® Rapid.
In 2019, IDL Biotech submitted a so-called Pre-submission request to the US FDA (United States Food and Drug Administration) this was done to ensure the future approval of UBC® Rapid, the companys rapid diagnostic test for bladder cancer. As of now, the company is...
Two new publications on UBC Rapid
A publication presented in Entropy shows the value of UBC® Rapid Read the press release here and here
IDL Biotech AB takes a first step in introducing the rapid test for bladder cancer, UBC® Rapid, in the USA
IDL Biotech has submitted supporting documents to the US FDA (Food and Drug Administration) to be able to obtain future approval of UBC® Rapid, the company's rapid test for bladder cancer. Read the press release here (in swedish)
Abstract shows the value of UBC Rapid
An abstract presented in Tumor Biology (July 2019: 1-74) shows the value of UB® Rapid, for accurate diagnosis and follow-up in bladder cancer. Read the press release here (in swedish)
German study recommends UBC® Rapid to be added in the diagnostics and follow-up of high risk bladder cancer
International Journal of Molecular Sciences has published a study on UBC® Rapid. In total 530 urine samples was included in the multicenterstudy. The author of the study concluded that elevated values of UBC® Rapid Test in urine are higher in patients with...
6 things you need to know about Bladder Cancer
Bladder cancer is the ninth most commonly diagnosed cancer in the world with an estimated 430 000 new cases reported in 2012. Men are more than three times more likely to get bladder cancer than women. Smoking is a major cause of bladder cancer. Exposure to industrial...
Positive results for UBC® Rapid in an Austrian study
International Journal of Medical Sciences has published an Austrian study with UBC® Rapid performed at the Department of Urology, Medical University of Innsbruck. Urinary samples were analyzed by cytology, UBC® Rapid and NMP22 BladderChek® test. The results from this...
UBC® Rapid is recommended to be added in the diagnostics of high grade bladder cancer tumours
Results from a published multicenter study The results from a German multicenter study were published in the latest issue of Tumor Biology. Principal investigator was Dr Thorsten Ecke at the Department of Urology, HELIOS Hospital, Bad Saarow. Urine samples were...
Positive results for UBC® Rapid in a Swedish multicenter study
The study published in Scandinavian Journal of Urology (https://www.ncbi.nlm.nih.gov/pubmed/28422550) was conducted at four Swedish hospitals; Uppsala University Hospital, Danderyds hospital, Enköping Hospital and Umeå University Hospital. Principal investigators was...